UNSPSC 51431504: Arfalasin

This classification denotes an angiotensin ii receptor antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E6SP93I57. European Medicines Agency schedules Arfalasin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05557MIG. Arfalasin generally arises in the molecular formula C48H67N13O11.

The term ARFALASIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 31, no10, 1977, list 17.) ARFALASIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule arfalasin under HS 29332990 and SITC 51573. As of Q4 2014, ARFALASIN remains the US FDA Preferred Term for this commodity. Arfalasin bears US NLM identifiers UMLS ID C0624820 and NCI Concept Code C87430.

UNSPSC 51431504 Arfalasin, a Commodity code, covers specific pharmaceutical products sourced by state and local health care and emergency services agencies. State and local governments procuring under this code buy individual medication line items — typically vials, injections, and other delivery forms of branded or generic pharmaceuticals — for use in emergency medical services, hospital systems, and public health programs. Solicitations under the code range from direct purchases of specific medications to framework agreements with manufacturers and distributors that serve multiple jurisdictions through cooperative purchasing vehicles. Issuing bodies include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Recent activity shows purchases by the City of Tampa's Purchasing Department on behalf of Tampa Fire Rescue and the Texas Health and Human Services Commission, alongside cooperative procurement through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP).

Recent solicitations span Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) on April 24, 2026, with a response deadline of April 8, 2026, seeking Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, representing preliminary market research before formal procurement. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and comply with cGMP and DSCSA certifications, with evaluation weighted 75 percent on price competitiveness.